Metabolic profiling of CHO-AβPP695 cells revealed mitochondrial dysfunction prior to amyloid-β pathology and potential therapeutic effects of both PPARγ and PPARα agonisms for Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 44, Issue 1, 2015, Pages 215-231

  Chang, Kai Lun ^a,b   Pee, Hai Ning ^a   Tan, Wee Pin ^a   Dawe, Gavin S ^c   Holmes, Elaine ^b   Nicholson, Jeremy K ^b   Chan, Eric C Y ^a   Ho, Paul C ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Alzheimer's disease; Amyloid beta protein precursor (A PP); Metabolomics; Metabonomics; Mitochondria; Pioglitazone; Rosiglitazone

Indexed keywords

AMYLOID BETA PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; AMYLOID BETA-PROTEIN (1-42); AMYLOID PRECURSOR PROTEIN; GLUCOSE; PEPTIDE FRAGMENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADHERENT CELL; ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CELL LYSATE; CELL MEMBRANE; CELL PROLIFERATION; CELL VIABILITY; CHO CELL LINE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FOLLOW UP; GAS CHROMATOGRAPHY; GENETIC TRANSFECTION; GLUCOSE TRANSPORT; METABOLOMICS; NONHUMAN; PRIORITY JOURNAL; THERAPY EFFECT; TIME OF FLIGHT MASS SPECTROMETRY; WESTERN BLOTTING; AGONISTS; ANIMAL; CELL DIFFERENTIATION; CRICETULUS; DISCRIMINANT ANALYSIS; DRUG EFFECTS; EXTRACELLULAR FLUID; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOUSE; MULTIVARIATE ANALYSIS; TIME;

AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHO CELLS; CRICETULUS; DISCRIMINANT ANALYSIS; EXTRACELLULAR FLUID; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; MICE; MULTIVARIATE ANALYSIS; PEPTIDE FRAGMENTS; PPAR ALPHA; PPAR GAMMA; THIAZOLIDINEDIONES; TIME FACTORS; TRANSFECTION;

EID: 84920792255     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140429     Document Type: Article

References (68)

1. Hanger DP, Anderton BH, Noble W (2009) Tau phosphorylation: The therapeutic challenge for neurodegenerative disease. Trends Mol Med 15, 112-119.
2. Wray S, Noble W (2009) Linking amyloid and tau pathology in Alzheimer's disease: The role of membrane cholesterol in Abeta-mediated tau toxicity. J Neurosci 29, 9665-9667.
3. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356.
4. Hardy JA, Higgins GA (1992) Alzheimer's disease: The amyloid cascade hypothesis. Science 256, 184-185.
5. Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer's disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov 10, 698-712.
6. Sperling R, Johnson K (2013) Biomarkers of Alzheimer disease: Current and future applications to diagnostic criteria. Continuum (Minneap Minn) 19, 325-338.
7. Peters KR, Lynn Beattie B, Feldman HH, Illes J (2013) A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease. Prog Neurobiol 110, 114-123.
8. Xu XH, Huang Y, Wang G, Chen SD (2012) Metabolomics: A novel approach to identify potential diagnostic biomarkers and pathogenesis in Alzheimer's disease. Neurosci Bull 28, 641-648.
9. Nicholson JK, Lindon JC, Holmes E (1999) 'Metabonomics': Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29, 1181-1189.
10. Urbanczyk-Wochniak E, Luedemann A, Kopka J, Selbig J, Roessner-Tunali U, Willmitzer L, Fernie AR (2003) Parallel analysis of transcript and metabolic profiles: A new approach in systems biology. EMBO Rep 4, 989-993.
11. Pasikanti KK, Ho PC, Chan EC (2008) Gas chromatography/ mass spectrometry in metabolic profiling of biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci 871, 202-211.
12. Teul J, Ruperez FJ, Garcia A, Vaysse J, Balayssac S, Gilard V, Malet-Martino M, Martin-Ventura JL, Blanco-Colio LM, Tunon J, Egido J, Barbas C (2009) Improving metabolite knowledge in stable atherosclerosis patients by association and correlation of GC-MS and 1H NMR fingerprints. J Proteome Res 8, 5580-5589.
13. Chang KL, New LS, Mal M, Goh CW, Aw CC, Browne ER, Chan EC (2011) Metabolic profiling of 3-nitropropionic acid early-stage Huntington's disease rat model using gas chromatography time-of-flight mass spectrometry. J Proteome Res 10, 2079-2087.
14. Nicholson JK, Lindon JC (2008) Systems biology: Metabonomics. Nature 455, 1054-1056.
15. Zhao S, Iyengar R (2012) Systems pharmacology: Network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol 52, 505-521.
16. Belyaev ND, Kellett KA, Beckett C, Makova NZ, Revett TJ, Nalivaeva NN, Hooper NM, Turner AJ (2010) The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a ß-secretase-dependent pathway. J Biol Chem 285, 41443-41454.
17. Trushina E, Nemutlu E, Zhang S, ChristensenT, CampJ, Mesa J, Siddiqui A, TamuraY, Sesaki H, Wengenack TM, Dzeja PP, Poduslo JF (2012) Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer's disease. PLoS One 7, e32737.
18. Trushina E, MielkeMM(2014) Recent advances in the application of metabolomics to Alzheimer's Disease. Biochim Biophys Acta 1842, 1232-1239.
19. Escribano L, Simon AM, Gimeno E, Cuadrado-Tejedor M, Lopez de Maturana R, Garcia-Osta A, Ricobaraza A, Perez- Mediavilla A, Del Rio J, Frechilla D (2010) Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: Mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 35, 1593-1604.
20. Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, Craft S, Landreth G, Linnamagi U, Sawchak S (2010) Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: Results from a randomized, doubleblind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 30, 131-146.
21. Nicolakakis N, Aboulkassim T, Ongali B, Lecrux C, Fernandes P, Rosa-Neto P, Tong XK, Hamel E (2008) Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J Neurosci 28, 9287-9296.
22. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6, 246-254.
23. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T (2011) Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 32, 1626-1633.
24. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: A preliminary study. Am J Geriatr Psychiatry 13, 950-958.
25. Woodcock J, Sharfstein JM, Hamburg M (2010) Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. N Engl J Med 363, 1489-1491.
26. Orasanu G, Ziouzenkova O, Devchand PR, Nehra V, Hamdy O, Horton ES, Plutzky J (2008) The peroxisome proliferatoractivated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptoralpha- dependent manner in vitro and in vivo in mice. J Am Coll Cardiol 52, 869-881.
27. Takeda (2013) Biomarker qualification for risk of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and safety and efficacy evaluation of pioglitazone in delaying its onset. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2013 Dec 03]. Available from: http://clinicaltrials.gov/show/NCT01931566NLMIdentifier: NCT01931566.
28. Birkenstock T, Liebeke M, Winstel V, Krismer B, Gekeler C, Niemiec MJ, Bisswanger H, Lalk M, Peschel A (2012) Exometabolome analysis identifies pyruvate dehydrogenase as a target for the antibiotic triphenylbismuthdichloride in multiresistant bacterial pathogens. J Biol Chem 287, 2887-2895.
29. Kell DB, Brown M, Davey HM, Dunn WB, Spasic I, Oliver SG (2005) Metabolic footprinting and systems biology: The medium is the message. Nat Rev Microbiol 3, 557-565.
30. Hazra S, Batra RK, Tai HH, Sharma S, Cui X, Dubinett SM (2007) Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15- hydroxyprostaglandin dehydrogenase. Mol Pharmacol 71, 1715-1720.
31. Lee G, Elwood F, McNally J, Weiszmann J, Lindstrom M, Amaral K, Nakamura M, Miao S, Cao P, Learned RM, Chen JL, Li Y (2002), T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem 277, 19649-19657.
32. Zaytseva YY, Wallis NK, Southard RC, Kilgore MW (2011) The PPARgamma antagonist T0070907 suppresses breast cancer cell proliferation and motility via both PPARgammadependent and -independent mechanisms. Anticancer Res 31, 813-823.
33. Ding L, Liang XG, Lou YJ (2007) Time-dependence of cardiomyocyte differentiation disturbed by peroxisome proliferator-activated receptor alpha inhibitor GW6471 in murine embryonic stem cells in vitro. Acta Pharmacol Sin 28, 634-642.
34. Garrido-Urbani S, Jemelin S, Deffert C, Carnesecchi S, Basset O, Szyndralewiez C, Heitz F, Page P, Montet X, Michalik L, Arbiser J, Ruegg C, Krause KH, Imhof BA (2011) Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARalpha mediated mechanism. PLoS One 6, e14665.
35. Chan EC, Pasikanti KK, Nicholson JK (2011) Global urinary metabolic profiling procedures using gas chromatographymass spectrometry. Nat Protoc 6, 1483-1499.
36. Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, Djoumbou Y, Mandal R, Aziat F, Dong E, Bouatra S, Sinelnikov I, Arndt D, Xia J, Liu P, Yallou F, Bjorndahl T, Perez-Pineiro R, Eisner R, Allen F, Neveu V, Greiner R, Scalbert A (2013)HMDB3.0-The Human Metabolome Database in 2013. Nucleic Acids Res 41, D801-D807.
37. Kanehisa M, Goto S, Sato Y, Furumichi M, TanabeM(2012) KEGGfor integration and interpretation of large-scale molecular data sets. Nucleic Acids Res 40, D109-D114.
38. Marroquin LD, Hynes J, Dykens JA, Jamieson JD, Will Y (2007) Circumventing the Crabtree effect: Replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol Sci 97, 539-547.
39. Krako N, Magnifico MC, Arese M, Meli G, Forte E, Lecci A, Manca A, Giuffre A, Mastronicola D, Sarti P, Cattaneo A (2013) Characterization of mitochondrial dysfunction in the 7PA2 cell model of Alzheimer's disease. J Alzheimers Dis 37, 747-758.
40. Meli G, Lecci A, Manca A, Krako N, Albertini V, Benussi L, Ghidoni R, Cattaneo A (2014) Conformational targeting of intracellular Abeta oligomers demonstrates their pathological oligomerization inside the endoplasmic reticulum. Nat Commun 5, 3867.
41. Portelius E, Olsson M, Brinkmalm G, Ruetschi U, Mattsson N, Andreasson U, Gobom J, Brinkmalm A, Holtta M, Blennow K, Zetterberg H (2013) Mass spectrometric characterization of amyloid-beta species in the 7PA2 cell model of Alzheimer's disease. J Alzheimers Dis 33, 85-93.
42. Sharples RA, Vella LJ, Nisbet RM, Naylor R, Perez K, Barnham KJ, Masters CL, Hill AF (2008) Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes. FASEB J 22, 1469-1478.
43. Zhou S, Zhou H, Walian PJ, JapBK(2005) CD147 is a regulatory subunit of the gamma-secretase complex in Alzheimer's disease amyloid beta-peptide production. Proc Natl Acad Sci U S A 102, 7499-7504.
44. Kovalevich J, Langford D (2013) Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology. Methods Mol Biol 1078, 9-21.
45. Anandatheerthavarada HK, Biswas G, Robin MA, Avadhani NG (2003) Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol 161, 41-54.
46. Pavlov PF, Wiehager B, Sakai J, Frykman S, Behbahani H, Winblad B, Ankarcrona M (2011) Mitochondrial gammasecretase participates in the metabolism of mitochondriaassociated amyloid precursor protein. FASEB J 25, 78-88.
47. Ferreira IL, Resende R, Ferreiro E, Rego AC, Pereira CF (2010) Multiple defects in energy metabolism in Alzheimer's disease. Curr Drug Targets 11, 1193-1206.
48. Chen JX, Yan SS (2010) Role of mitochondrial amyloid-beta in Alzheimer's disease. J Alzheimers Dis 20(Suppl 2), S569-S578.
49. Kim EJ, Cho SS, Jeong Y, Park KC, Kang SJ, Kang E, Kim SE, Lee KH, NaDL(2005) Glucose metabolism in early onset versus late onset Alzheimer's disease:AnSPManalysis of 120 patients. Brain 128, 1790-1801.
50. Chen JX, Yan SD (2007) Amyloid-beta-induced mitochondrial dysfunction. J Alzheimers Dis 12, 177-184.
51. Galindo MF, Ikuta I, Zhu X, Casadesus G, Jordan J (2010) Mitochondrial biology in Alzheimer's disease pathogenesis. J Neurochem 114, 933-945.
52. Greene JG, Greenamyre JT (1995) Characterization of the excitotoxic potential of the reversible succinate dehydrogenase inhibitor malonate. J Neurochem 64, 430-436.
53. Greene JG, Porter RH, Eller RV, Greenamyre JT (1993) Inhibition of succinate dehydrogenase by malonic acid produces an "excitotoxic" lesion in rat striatum. J Neurochem 61, 1151-1154.
54. Morath MA, Okun JG, Muller IB, Sauer SW, Horster F, Hoffmann GF, Kolker S (2008) Neurodegeneration and chronic renal failure in methylmalonic aciduria-a pathophysiological approach. J Inherit Metab Dis 31, 35-43.
55. McCracken C, Hudson P, Ellis R, McCaddon A (2006) Methylmalonic acid and cognitive function in the Medical Research Council Cognitive Function and Ageing Study. Am J Clin Nutr 84, 1406-1411.
56. Fonteh AN, Harrington RJ, Tsai A, Liao P, Harrington MG (2007) Free amino acid and dipeptide changes in the body fluids from Alzheimer's disease subjects. Amino Acids 32, 213-224.
57. Mandrekar-Colucci S, Landreth GE (2011) Nuclear receptors as therapeutic targets for Alzheimer's disease. Expert Opin Ther Targets 15, 1085-1097.
58. Masciopinto F, Di Pietro N, Corona C, Bomba M, Pipino C, Curcio M, Di Castelnuovo A, Ciavardelli D, Silvestri E, Canzoniero LM, Sekler I, Pandolfi A, Sensi SL (2012) Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice. Cell Death Dis 3, e448.
59. Papadopoulos P, Rosa-Neto P, Rochford J, Hamel E (2013) Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer's disease with combined amyloid-beta and cerebrovascular pathology. PLoS One 8, e68612.
60. Reifel-Miller A, Otto K, Hawkins E, Barr R, Bensch WR, Bull C, Dana S, Klausing K, Martin JA, Rafaeloff-Phail R, Rafizadeh-Montrose C, Rhodes G, Robey R, Rojo I, Rungta D, Snyder D, Wilbur K, Zhang T, Zink R, Warshawsky A, Brozinick JT (2005) A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia. Mol Endocrinol 19, 1593-1605.
61. Atherton HJ, Bailey NJ, ZhangW, Taylor. J, Major H, Shockcor J, Clarke K, Griffin JL (2006) A combined 1H-NMR spectroscopy- and mass spectrometry-based metabolomic study of the PPAR-alpha null mutant mouse defines profound systemic changes in metabolism linked to the metabolic syndrome. Physiol Genomics 27, 178-186.
62. Satapati S, He T, Inagaki T, Potthoff M, Merritt ME, Esser V, Mangelsdorf DJ, Kliewer SA, Browning JD, Burgess SC (2008) Partial resistance to peroxisome proliferatoractivated receptor-alpha agonists in ZDF rats is associated with defective hepatic mitochondrial metabolism. Diabetes 57, 2012-2021.
63. Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, Evert BO, Dumitrescu-Ozimek L, Thal DR, Landreth G, Walter J, Klockgether T, van Leuven F, Heneka MT (2006) Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A 103, 443-448.
64. Liu LP, Yan TH, Jiang LY, Hu W, Hu M, Wang C, Zhang Q, Long Y, Wang JQ, Li YQ, Hu M, Hong H (2013) Pioglitazone ameliorates memory deficits in streptozotocininduced diabetic mice by reducing brain beta-amyloid through PPARgamma activation. Acta Pharmacol Sin 34, 455-463.
65. Minnich A, Tian N, Byan L, BilderG(2001)Apotent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle. Am J Physiol Endocrinol Metab 280, E270-E279.
66. Cree MG, Newcomer BR, Herndon DN, Qian T, Sun D, Morio B, Zwetsloot JJ, Dohm GL, Fram RY, Mlcak RP, Aarsland A, Wolfe RR (2007) PPAR-alpha agonism improves whole body and muscle mitochondrial fat oxidation, but does not alter intracellular fat concentrations in burn trauma children in a randomized controlled trial. Nutr Metab (Lond) 4, 9.
67. Geldmacher DS, Fritsch T, McClendon MJ, Landreth G (2011)Arandomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol 68, 45-50.
68. Imaizumi Y, Okano H (2014) Modeling human neurological disorders with induced pluripotent stem cells. J Neurochem 129, 388-399.